Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

NCT02016105 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

465

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Type Psoriasis

Interventions

DRUG: GP2017 Adalimumab
DRUG: Humira ® Adalimumab

Sponsor

Sandoz

Collaborators

[object Object]